8. Huntington disease Clinical trials / Disease details


Clinical trials : 229 Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-011743-39-GB
(EUCTR)
15/12/200921/08/2009A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing choreaA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea Huntington's disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
64Germany;United Kingdom
2NCT01019473
(ClinicalTrials.gov)
November 200919/11/2009Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing ChoreaA Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing ChoreaHuntington's Disease;ChoreaDrug: AFQ056;Drug: PlaceboNovartis PharmaceuticalsNULLTerminated30 Years85 YearsBoth44Phase 2Germany;United Kingdom
3EUCTR2009-011743-39-DE
(EUCTR)
18/09/200920/08/2009Efficacy, Safety and Tolerability of AFQ056 in Patients with Huntington's Disease in Reducing ChoreaA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea Huntington's disease
MedDRA version: 13.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
60United States;Germany;United Kingdom